213316-49-5

Basic information

• Product Name: (1R,2S)-1-BOC-AMINO-2-VINYLCYCLOPROPANECARBOXYLIC ACID ETHYL ESTER
• Synonyms: (1R,2S)-1-BOC-AMINO-2-VINYLCYCLOPROPANECARBOXYLIC ACID ETHYL ESTER;N-BOC-(1R,2S)-1-AMINO-2-VINYLCYCLOPROPANE CARBOXYLIC ACID ETHYL ESTER;Cyclopropanecarboxylic acid, 1-[[(1,1-dimethylethoxy)carbonyl]amino]-2-ethenyl-, ethyl ester, (1R,2S)-rel-;N-BOC-(1R,2S)-1-AMINO-2-VINYLCYCLOPROPANE CARBOXYL;(1R,2S)-1-[[(tert-Butoxy)carbonyl]amino]-2-ethenyl-cyclopropanecarboxylic acid ethyl ester;(1R,2S)-rel-1-[[(1,1-diMethylethoxy)carbonyl]aMino]-2-ethenyl-Cyclopropanecarboxylic acid ethyl ester;(1R,2S)-1-boc aMino-2-ethenyl cyclopropane forMaic acid;N-BOC-(1R,2S)-1-AMINO-2-VIYCYCLOPROPANE CARBOXYL
• CAS NO: 213316-49-5
• Molecular Formula: C13H21NO4
• Molecular Weight: 255.31
• EINECS: 1533716-785-6
• Product Categories: Amino Acid Derivatives
• Mol File: 213316-49-5.mol

Chemical Properties

• Boiling Point: 328.42 °C at 760 mmHg
• Flash Point: 152.423 °C
• Appearance: /
• Density: 1.08
• Storage Temp.: 2-8°C
• CAS DataBase Reference: (1R,2S)-1-BOC-AMINO-2-VINYLCYCLOPROPANECARBOXYLIC ACID ETHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: (1R,2S)-1-BOC-AMINO-2-VINYLCYCLOPROPANECARBOXYLIC ACID ETHYL ESTER(213316-49-5)
• EPA Substance Registry System: (1R,2S)-1-BOC-AMINO-2-VINYLCYCLOPROPANECARBOXYLIC ACID ETHYL ESTER(213316-49-5)

Safety Data

• Hazardous Substances Data: 213316-49-5(Hazardous Substances Data)

Usage

Chemical Properties

White powder

InChI:O=C(OCC)[C@]1(NC(=O)OC(C)(C)C)[C@H](\C=C)C1

Upstream product

• 259214-54-5 (trans)-ethyl 1-amino-2-vinylcyclopropanecarboxylate hydrochloride 
• 34619-03-9 tert-butyldicarbonate 
• 787548-29-2 (1R,2S)/(1S,2R) 1-amino-2-vinylcyclopropane carboxylic acid ethyl ester 
• 24424-99-5 di-tert-butyl dicarbonate 
• 213316-32-6 rac-(1R,2S)-1-amino-2-vinylcyclopropanecarboxylic acid ethyl ester 
• 259217-95-3 N-Boc-(1R,2S)-1-amino-2-vinylcyclopropane carboxylic acid ethyl ester 
• 681807-59-0 (1R,2S)-ethyl 1-(tert-butoxycarbonylamino)-2-vinylcyclopropanecarboxylate 
• 821-06-7 (E)-1,4-dibromobutene 
• 40682-54-0 ethyl N-benzylideneglycinate 
• 1393095-18-5 (E)-ethyl 1-(benzylideneamino)-2-vinylcyclopropanecarboxylate 
• 141-78-6 ethyl acetate 
• 681807-60-3 (1R,2S)-ethyl 1-amino-2-vinylcyclopropanecarboxylate hydrochloride 
• 1159609-95-6 (1R,2S)-1-amino-2-vinylcyclopropanecarboxylic acid ethyl ester tosylate salt 
• 1023795-84-7 C₂₁H₂₁NO₂ 

Downstream Products

• 1201943-62-5 1-tert-butoxycarbonylamino-2-vinylcyclopropanecarboxylic acid methyl ester 
• 259214-55-6 (1S,2R)-1-tert-butoxycarbonylamino-2-vinylcyclopropanecarboxylic acid 
• 259217-95-3 N-Boc-(1R,2S)-1-amino-2-vinylcyclopropane carboxylic acid ethyl ester 
• 1201943-62-5 (1S,2R)-1-tert-butoxycarbonylamino-2-vinylcyclopropanecarboxylic acid methyl ester 
• 159622-09-0 (1R,2S)-1-tert-butoxycarbonylamino-2-vinyl-cyclopropanecarboxylic acid methyl ester 
• 259214-54-5 (trans)-ethyl 1-amino-2-vinylcyclopropanecarboxylate hydrochloride 
• 924307-75-5 (1S,2R)-ethyl 2-vinyl-1-(tert-butoxycarbonylamino)cyclopropanecarboxylate 
• 213316-32-6 rac-(1R,2S)-1-amino-2-vinylcyclopropanecarboxylic acid ethyl ester 
• 259214-54-5 ethyl (1R,2S)-1-amino-2-vinylcyclopropanecarboxylate hydrochloride 
• 630421-48-6 tert-butyl ((1R,2S)-1-{[(cyclopropylsulfonyl)amino]carbonyl}-2-vinylcyclopropyl)carbamate 
• 630421-49-7 (1R,2S)-1-amino-N-(cyclopropylsulfonyl)-2-vinylcyclopropanecarboxamide hydrochloride 
• 1028252-79-0 C₃₁H₃₁F₃N₄O₇S 
• 1028252-78-9 C₃₆H₃₉F₃N₄O₉S 
• 1028329-00-1 C₃₇H₄₂F₃N₅O₈S 

Relevant articles and documents

CALPAIN MODULATORS AND METHODS OF PRODUCTION AND USE THEREOF

The present technology relates to compounds, kits, compositions, and methods useful for the treatment of fibrotic disease. In some aspects, the present technology provides for treatment of various diseases or disorders associated or mediated, at least in part, by calpains, such as CAPN1, CAPN2, and/or CAPN9. The present technology is generally applicable to compounds which inhibit myofibroblast differentiation.

Class of large ring heterocyclic compound restraining HCV and manufacturing and uses thereof

The invention relates to a class of compounds that inhibit HCV. The compounds are represented by Formula A. The invention also relates to preparation and pharmaceutical use of the compounds.

COMPOUNDS AS HEPATITIS C INHIBITORS AND USES THEREOF IN MEDICINE

Provided herein are compounds as hepatitis C inhibitors and uses thereof in medicine. Specifically, provided herein is a compound of Formula (I) or a stereoisomer, a tautomer, an enantiomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, which can be used for treating HCV infection or hepatitis C diseases. Also provided herein are a pharmaceutically acceptable composition containing such compound and a method of treating HCV infection or hepatitis C diseases comprising administering the compound or pharmaceutical composition thereof disclosed herein.

Macrocyclic compounds for suppressing replication of hepatitis C virus

A compound as represented by Formula (I) is provided, wherein groups are defined in the description. The compound is used as HCV protease inhibitor for treating HCV infection.

MACROCYCLIC COMPOUNDS FOR SUPPRESSING REPLICATION OF HEPATITIS C VIRUS

A compound as represented by Formula (I) is provided, wherein groups are defined in the description. The compound is used as HCV protease inhibitor for treating HCV infection.

Dynamic kinetic resolution of dehydrocoronamic acid

Dehydrocoronamic acid can be racemised by dehydration of an N-acyl derivative to an azlactone, which undergoes facile racemisation. For the N-trifluoroacetyl derivative, the racemisation process was combined with an enzymatic resolution, to achieve a dynamic kinetic resolution process by which the racemate can be converted to either enantiomer. This journal is the Partner Organisations 2014.

METHOD FOR PRODUCING 1-AMINO-1-ALKOXYCARBONYL-2-VINYLCYCLOPROPANE

It is an object of the present invention to provide a novel method for producing (1R,2S)/(1S,2R)-1-amino-1-alkoxycarbonyl-2-vinylcyclopropane which is useful as a synthetic intermediate of therapeutic agents for hepatitis C and a synthetic intermediate thereof. According to the present invention, when a trans-2-butene derivative having a leaving group at each of the 1- and 4-positions is reacted with a malonic ester in the presence of a base, a specific amount of an alkali metal alkoxide or an alkali metal hydride is used as the base, and further a specific amount of a malonic ester is used to produce a cyclopropane diester, and further, chiral or achiral 1-amino-1-alkoxy-carbonyl-2-vinylcyclopropane and a salt thereof are synthesized using the cyclopropane diester.

Hepatitis C Virus Inhibitors

Hepatitis C virus inhibitors having the general formula are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

MACROCYCLIC PEPTIDES AS HEPATITIS C VIRUS INHIBITORS

Macrocyclic peptides having the general formula (I): are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

Hepatitis C Virus Inhibitors

Hepatitis C virus inhibitors having the general formula are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.